Marta L. Davila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marta L. Davila has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Brian R. Weston
Departments of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
3 shared publications Ethan Miller
3 shared publications- Gottumukkala Subba Raju
The University of Texas MD Anderson Cancer Center
3 shared publications John R. Stroehlein
3 shared publicationsManoop S. Bhutani
3 shared publications- Patrick M. Lynch
University of Texas M. D. Anderson Cancer, Center
3 shared publications
Latest Publications
- 29 August 2022
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 51 (3) , XIII-XIV
Recent Advancements in the Diagnosis and Treatment of Gastrointestinal Cancers
- 29 August 2022
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 51 (3) , XIII-XIV
Recent Advancements in the Diagnosis and Treatment of Gastrointestinal Cancers
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB363
Su1611 Outcome of a Protocol Driven Endoscopic Resection of Patients With Large Colon Polyps (>20 MM) Results in Low Complications and Recurrence
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB363
Su1611 Outcome of a Protocol Driven Endoscopic Resection of Patients With Large Colon Polyps (>20 MM) Results in Low Complications and Recurrence
- 1 May 2015
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 81 (5) , AB256
Sa1546 Outcome of Management of Colon Polyps Larger Than 20 mm At a Referral Endoscopic Mucosal Resection Center
- 1 May 2015
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 81 (5) , AB256
Sa1546 Outcome of Management of Colon Polyps Larger Than 20 mm At a Referral Endoscopic Mucosal Resection Center
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB116-AB117
166 Natural Language Processing (NLP) As an Alternative to Manual Reporting of Colonoscopy Quality Metrics
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB116-AB117
166 Natural Language Processing (NLP) As an Alternative to Manual Reporting of Colonoscopy Quality Metrics
- 1 November 2013
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 23 (4) , 479-489
Endoscopic Management of Barrett's Esophagus with High-Grade Dysplasia and Early-Stage Esophageal Adenocarcinoma
- 1 November 2013
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 23 (4) , 479-489
Endoscopic Management of Barrett's Esophagus with High-Grade Dysplasia and Early-Stage Esophageal Adenocarcinoma
- 2 March 2011
- Published by Springer Nature in Current Oncology Reports
- Vol. 13 (3) , 157-167
Update: Modern Approaches to the Treatment of Localized Esophageal Cancer
The optimal treatment strategy for esophageal cancer continues to be a topic of debate. Improvements in chemotherapy drugs, surgical techniques, and radiotherapy planning and delivery have led to the design of treatment approaches that are specific to both the stage of the tumor and the overall performance status of the patient. Surgery continues to be the standard treatment option for localized disease, but multimodality treatments that include radiation and chemotherapy with surgery are increasingly used. The next few years will continue to see improvements in radiation techniques, especially proton beam treatment; the development of additional minimally invasive surgical approaches to minimize postoperative side effects; and the discovery of molecular biomarkers to help specifically target treatment of esophageal cancer in individual patients.
- 2 March 2011
- Published by Springer Nature in Current Oncology Reports
- Vol. 13 (3) , 157-167
Update: Modern Approaches to the Treatment of Localized Esophageal Cancer
The optimal treatment strategy for esophageal cancer continues to be a topic of debate. Improvements in chemotherapy drugs, surgical techniques, and radiotherapy planning and delivery have led to the design of treatment approaches that are specific to both the stage of the tumor and the overall performance status of the patient. Surgery continues to be the standard treatment option for localized disease, but multimodality treatments that include radiation and chemotherapy with surgery are increasingly used. The next few years will continue to see improvements in radiation techniques, especially proton beam treatment; the development of additional minimally invasive surgical approaches to minimize postoperative side effects; and the discovery of molecular biomarkers to help specifically target treatment of esophageal cancer in individual patients.
- 1 January 2011
- Published by Elsevier in Gastrointestinal Endoscopy Clinics of North America
- Vol. 21 (1) , 67-79
Photodynamic Therapy
- 1 January 2011
- Published by Elsevier in Gastrointestinal Endoscopy Clinics of North America
- Vol. 21 (1) , 67-79
Photodynamic Therapy
- 1 March 2007
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 9 (2) , 116-120
Neutropenic enterocolitis: Current issues in diagnosis and management
Neutropenic enterocolitis or typhlitis (from the Greek word typhlon, meaning cecum) is a clinical syndrome that occurs in the setting of disease or chemotherapy-induced neutropenia. The disease is characterized by an inflammatory process involving colon and/or small bowel, and it can result in ischemia, necrosis, bacteremia, hemorrhage, and perforation. The classic clinical features include fever and abdominal pain. The diagnosis is supported by the findings of bowel wall thickening on ultrasonography or CT imaging. The management of neutropenic enterocolitis is controversial. Neither prospective nor high-quality retrospective studies concerning medical or surgical therapies are available. Most authors will recommend initial conservative management with bowel rest, intravenous fluids, total parenteral nutrition, broad-spectrum antibiotics and normalization of neutrophil counts. Surgical intervention is recommended in the setting of obstruction, perforation, persistent gastrointestinal bleeding despite correction of thrombocytopenia and coagulopathy, and clinical deterioration.
- 1 March 2007
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 9 (2) , 116-120
Neutropenic enterocolitis: Current issues in diagnosis and management
Neutropenic enterocolitis or typhlitis (from the Greek word typhlon, meaning cecum) is a clinical syndrome that occurs in the setting of disease or chemotherapy-induced neutropenia. The disease is characterized by an inflammatory process involving colon and/or small bowel, and it can result in ischemia, necrosis, bacteremia, hemorrhage, and perforation. The classic clinical features include fever and abdominal pain. The diagnosis is supported by the findings of bowel wall thickening on ultrasonography or CT imaging. The management of neutropenic enterocolitis is controversial. Neither prospective nor high-quality retrospective studies concerning medical or surgical therapies are available. Most authors will recommend initial conservative management with bowel rest, intravenous fluids, total parenteral nutrition, broad-spectrum antibiotics and normalization of neutrophil counts. Surgical intervention is recommended in the setting of obstruction, perforation, persistent gastrointestinal bleeding despite correction of thrombocytopenia and coagulopathy, and clinical deterioration.
- 1 June 2006
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 9 (3) , 249-255
Neutropenic enterocolitis
Neutropenic enterocolitis is a life-threatening gastrointestinal (GI) complication of chemotherapy most often associated with leukemia or lymphoma. Early recognition and treatment are essential for survival. The management of neutropenic enterocolitis is controversial. Neither prospective nor high-quality retrospective studies concerning medical or surgical therapies are available. Treatment approaches have been derived mostly from small case studies and retrospective reports. Therefore, a uniform management strategy cannot be recommended. The best strategy appears to be an individualized approach to each case given the wide spectrum of presentation. There is general agreement that early management should be conservative and should consist of bowel rest, intravenous fluid administration, total parenteral nutrition, broad-spectrum antibiotics, and normalization of neutrophil counts. Surgical intervention is warranted in the setting of perforation, obstruction, clinical deterioration suggestive of uncontrolled sepsis, and persistent GI bleeding despite correction of cytopenias and coagulopathy.
- 1 June 2006
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 9 (3) , 249-255
Neutropenic enterocolitis
Neutropenic enterocolitis is a life-threatening gastrointestinal (GI) complication of chemotherapy most often associated with leukemia or lymphoma. Early recognition and treatment are essential for survival. The management of neutropenic enterocolitis is controversial. Neither prospective nor high-quality retrospective studies concerning medical or surgical therapies are available. Treatment approaches have been derived mostly from small case studies and retrospective reports. Therefore, a uniform management strategy cannot be recommended. The best strategy appears to be an individualized approach to each case given the wide spectrum of presentation. There is general agreement that early management should be conservative and should consist of bowel rest, intravenous fluid administration, total parenteral nutrition, broad-spectrum antibiotics, and normalization of neutrophil counts. Surgical intervention is warranted in the setting of perforation, obstruction, clinical deterioration suggestive of uncontrolled sepsis, and persistent GI bleeding despite correction of cytopenias and coagulopathy.
- 1 April 2006
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 5 (2) , 194-197
Neutropenic enterocolitis
This review will cover the recent literature pertaining to the pathogenesis, diagnosis, and management of patients with neutropenic enterocolitis. Neutropenic enterocolitis, also referred to as typhlitis, is a life-threatening gastrointestinal complication of chemotherapy, most often associated with leukemia or lymphoma. Recently, a larger number of reports have been published of individuals presenting with this syndrome after being treated with newer chemotherapeutic agents for solid tumors such as non-small cell lung, ovarian, and peritoneal cancer, as well as following autologous stem cell transplantation. Recent studies have also better characterized computed tomographic and ultrasonographic features of this entity that can help differentiate neutropenic enterocolitis from other gastrointestinal complications. A newly published systematic analysis of the literature, which included 145 articles, defines appropriate diagnostic criteria and treatment recommendations. Neutropenic enterocolitis is a serious, potentially lethal complication of anticancer therapy. The studies discussed in this review will help the practitioner make an appropriate, early diagnosis and implement a therapeutic program that would improve the outcome of these patients.
- 1 April 2006
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 5 (2) , 194-197
Neutropenic enterocolitis
This review will cover the recent literature pertaining to the pathogenesis, diagnosis, and management of patients with neutropenic enterocolitis. Neutropenic enterocolitis, also referred to as typhlitis, is a life-threatening gastrointestinal complication of chemotherapy, most often associated with leukemia or lymphoma. Recently, a larger number of reports have been published of individuals presenting with this syndrome after being treated with newer chemotherapeutic agents for solid tumors such as non-small cell lung, ovarian, and peritoneal cancer, as well as following autologous stem cell transplantation. Recent studies have also better characterized computed tomographic and ultrasonographic features of this entity that can help differentiate neutropenic enterocolitis from other gastrointestinal complications. A newly published systematic analysis of the literature, which included 145 articles, defines appropriate diagnostic criteria and treatment recommendations. Neutropenic enterocolitis is a serious, potentially lethal complication of anticancer therapy. The studies discussed in this review will help the practitioner make an appropriate, early diagnosis and implement a therapeutic program that would improve the outcome of these patients.